The MS5701 low pressure sensor is offered with an I2C or SPI digital interface. Available in either differential or gauge models, the MS5701 can measure as low as ±2.5 in. H2O up to ±10 in. H2O in a differential version.
Spectrum Advanced Specialty Products offers a new L circuit EMI filter designed to provide both inductance and series resistance for superior transient performance.
The 300 Series compact-sized pressure transducer delivers long term stability during operation. The transducer is excellent for use in dynamic or static measurement.
Edmund Optics (EO), a provider of optical components, expands its selection of TECHSPEC MgF2 coated achromatic lenses. Consisting of two optical components cemented together to form an achromatic doublet...
Product testing is a critical component in the development of a medical device. But how many engineers truly understand the importance of what are arguably the three most crucial tests for a medical device? This article reviews these three tests–cytotoxicity, sensitization, and irritation–and offers some insight that will ideally make them go more smoothly for engineers.
Applimotion’s UTS Series direct drive slotless motors now cover 29 to 240 mm diameters with thin radial length, prefect for direct drive positioning or high speed spindle applications.
How Are You Influencing Wireless Medical Technology?
Asking the right questions when selecting a high performance plastic for micromolding an MIS device could reap some great competitive advantages. This article will review the micromolding process and cover the important aspects of each question that should be addressed by the outsourcing partner, the OEM, or both.
Quark Pharmaceuticals and Major Pharmaceutical Company Enter into Licensing Option Agreement for the p53 Suppressor Drug QPI-1002, the First siRNA Administered Systemically in...August 18, 2010 4:36 am | News | Comments
FREMONT, Calif., Aug. 18 /- Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor...
Cardiac DimensionsÃ‚® Announces Presentation of 12-Month Follow-up Data of TITANâ„¢ Trial at European Society of Cardiology MeetingAugust 18, 2010 4:36 am | News | Comments
KIRKLAND, Wash., Aug. 18 /- Cardiac Dimensions, an early stage company focused on the development of minimally invasive devices for the treatment of mitral valve disease and congestive heart failure, announced today that the 12-month follow-up results from the TITAN™ trial of the...
(Southern Methodist University) New research holds promise for people whose cancer has spread to their bones. A common treatment for such patients is radiosurgery ? even though little is known about its impact on bone strength, says Edmond Richer at Southern Methodist University, Dallas....
Turning a â€œcool ideaâ€ into the â€œnext big thingâ€ takes perserverence, an unwavering commitment to a vision, and usually, in the life sciences, a boatload of cash. Local entrepreneurs say the challenge lies in convincing funders (or customers) of the value proposition of the product.
In this issue we set out to address a core question: How do different types of life sciences companies make money? Yet, there's another question that we also felt it was important to address: Can a company work for the public good even when there is little or no hope of turning a profit?
Two Boston VCs known for not being shy of risk, SV Life Sciences' James Garvey and PureTech Ventures' Daphne Zohar, told Mass High Tech where they're applying a higher level of scrutiny before investing and what life science categories they're avoiding like the plague.
After getting off to a false start in the 1990s, the field of regenerative medicine has been reborn over the past decade. Now, several New England companies are showing that regenerative medicine - generally defined as therapy that uses living cells to repair the body - is more than just...